Gene Therapy pp 313-347 | Cite as

Identification of Tumor Antigens Defined by Cytolytic T Lymphocytes and Therapeutic Implications

  • Th. Wölfel
Chapter

Abstract

The hope that tumors can be destroyed by the autologous immune system, like foreign infectious agents, is almost as old as the discoveries of immune defense mechanisms [1]. Herein, the focus is on tumor antigens recognized by cytolytic T lymphocytes (CTL). The identification of CTL-defined tumor rejection antigens in animal models motivated the search for comparable antigens on human tumors. The current knowledge on murine and human tumor antigens recognized by the T cell system is reviewed, thereby excluding viral antigens [reviewed in: [2, 3]]. Further, the potential role of these antigens as targets of rejection responses and inducers of immune protection will be discussed.

Keywords

Melanoma Cell Tumor Antigen Melanoma Patient Human Melanoma Tumor Rejection 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Ehrlich, P (1909) Ueber den jetzigen Stand der Karzinomforschung. Ned. Tijdschr. Geneeskd. 1: 273–290.Google Scholar
  2. 2.
    Masucci, M. G (1993) Viral immunopathology of human tumors. Curr. Opin. Immunol. 5: 693–700.PubMedCrossRefGoogle Scholar
  3. 3.
    Melief, C. J., W. M. Kast (1995) T-cell immunotherapy of tumors by adoptive transfer of cytotoxic T lymphocytes and by vaccination with minimal essential epitopes. Immunol. Rev. 145: 167–77.PubMedCrossRefGoogle Scholar
  4. 4.
    Gross, L (1943) Intradermal immunization of C3H mice against a sarcoma that originated in an animal of the same line. Cancer Res. 3: 326–333.Google Scholar
  5. 5.
    Foley, E. J (1953) Antigenic properties of methylcholanthrene-induced tumors in mice of the strain of origin. Cancer Res. 13: 835–837.PubMedGoogle Scholar
  6. 6.
    Prehn, R. T., J. M. Main (1957) Immunity to methylcholanthrene-induced sarcomas. J. Nat. Cancer Inst. 18: 769–778.PubMedGoogle Scholar
  7. 7.
    Klein, G., Sjogren, H. O., Klein, E., Hellström, K. E (1960) Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochtonous host. Cancer Res. 20: 1561–1572.PubMedGoogle Scholar
  8. 8.
    Kripke, M. L (1974) Antigenicity of murine skin tumors induced by ultraviolet light. J. Nat. Cancer Inst. 53: 1333.PubMedGoogle Scholar
  9. 9.
    Ward, P. L., H. Koeppen, T. Hurteau, H. Schreiber (1989) Tumor antigens defined by cloned immunological probes are highly polymorphic and are not detected on autologous normal cells. J. Exp. Med. 170: 217–32.PubMedCrossRefGoogle Scholar
  10. 10.
    Hewitt, H. B., E. R. Blake, A. S. Walder (1976) A critique of the evidence for active host defence against cancer, based on personal studies of 27 murine tumours of spontaneous origin. Brit. J. Cancer 33: 241–259.PubMedCrossRefGoogle Scholar
  11. 11.
    Middle, J. G., M. J. Embleton (1981) Naturally arising tumors in the inbred WAB/Not rat strain. II. Immunogenicity of transplanted tumors. J. Nat. Cancer Inst. 67: 637–643.PubMedGoogle Scholar
  12. 12.
    Van Pel, A., E Vessiére, T. Boon (1983) Protection against two spontaneous mouse leukemias conferred by immunogenic variants obtained by mutagenesis. J. Exp. Med. 157: 1992–2001.PubMedCrossRefGoogle Scholar
  13. 13.
    Hui, K. M., T. Sim, T. T. Foo, A. A. Oei (1989) Tumor rejection mediated by transfection with allogeneic class I histocompatibility gene. J. Immunol. 143: 3835–3843.PubMedGoogle Scholar
  14. 14.
    Grohmann, U., R. Bianchi, M. C. Fioretti, F. Fallarino, L. Binaglia, C. Uyttenhove, A. Van Pel, T. Boon, P. Puccetti (1995) CD8+ cell activation to a major mastocytoma rejection antigen, P815AB: requirement for tumor helper peptides in priming for skin test reactivity to a P815AB-related peptide. Eur. J. Immunol. 25: 2797–2802.PubMedCrossRefGoogle Scholar
  15. 15.
    Boon, T (1983) Antigenic tumor cell variants obtained with mutagens. Adv. Cancer Res. 39: 121–151.PubMedCrossRefGoogle Scholar
  16. 16.
    Schirrmacher, V (1992) Immunity and metastasis: In situ activation of protective T cells by virus modified cancer vaccines. Cancer Surv. 13: 129–154.PubMedGoogle Scholar
  17. 17.
    Colombo, M. P., G. Forni (1994) Cytokine gene transfer in tumor inhibition and tumor therapy. Immunol. Today 15: 48–51.PubMedCrossRefGoogle Scholar
  18. 18.
    Melief, C. J. M (1992) Tumor eradication by adoptive transfer of cytotoxic T lymphocytes. Adv. Cancer Res. 58: 143–175.PubMedCrossRefGoogle Scholar
  19. 19.
    Greenberg, P. D (1991) Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv. Immunol. 49: 281–355.PubMedCrossRefGoogle Scholar
  20. 20.
    Srivastava, P. K., A. B. DeLeo, L. J. Old (1986) Tumor rejection antigens of chemically induced tumors of inbred mice. Proc. Natl. Acad. Sci. USA 83: 3407–3411.PubMedCrossRefGoogle Scholar
  21. 21.
    Srivastava, P. K., R. G. Maki (1991) Stress-induced proteins in immune response to cancer. Curr. Top. Microbiol. Immunol. 167: 109–123.PubMedCrossRefGoogle Scholar
  22. 22.
    Uduno, H., D. L. Levey, P. K. Srivastava (1994) Cellular requirements for tumor-specific immunity elicited by heat shock proteins: tumor rejection antigen gp96 primes CD8+ T cells in vivo. Proc. Natl. Acad. Sci. 91: 3077–3081.CrossRefGoogle Scholar
  23. 23.
    Suto, R., P. K. Srivastava (1995) A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides. Science 269: 1585–1588.PubMedCrossRefGoogle Scholar
  24. 24.
    Wölfel, T., Van Pel, A., De Plaen, E., Lurquin, C., Maryanski, J. and Boon, T (1987) Immunogenic (tum) variants obtained by mutagenesis of mouse mastocytoma P815. VIII. Detection of stable transfectants expressing a tum antigen with a cytolytic T cell stimulation assay. Immunogenetics 26: 178–187.PubMedCrossRefGoogle Scholar
  25. 25.
    De Plaen, E., Lurquin, C., Van Pel, A., Mariame, B., Szikora, J. -P., Wölfel, T., Sibille, C., Chomez, P. and Boon, T (1988) Immunogenic (tum) variants of mouse tumor P815: Cloning of the gene of tum-antigen P91A and identification of the tum mutation. Proc. Natl. Acad. Sci. USA 85: 2274–2278.PubMedCrossRefGoogle Scholar
  26. 26.
    Lurquin, C., A. Van Pel, B. Mariame, E. De Plaen, J. -E. Szikora, C. Janssens, M. J. Reddehase, J. Lejeune, T. Boon (1989) Structure of the gene of tum-transplantation antigen P91A: the mutated exon encodes a peptide recognized with Ld by cytolytic T cells. Cell 58: 293–303.PubMedCrossRefGoogle Scholar
  27. 27.
    Sibille, C., P. Chomez, C. Wildmann, A. Van Pel, E. De Plaen, J. L. Maryanski, V. de Bergeyck, T. Boon (1990) Structure of the gene coding for tum transplantation antigen P198: a point mutation generates a new antigenic peptide. J. Exp. Med. 172: 35–45.PubMedCrossRefGoogle Scholar
  28. 28.
    Szikora, J. -P., A. Van Pel, V. Brichard, M. André, N. Van Baren, P. Henry, E. De Plaen, T. Boon (1990) Structure of the gene of turn-transplantation antigen P35B: presence of a point mutation in the antigenic allele. EMBO J. 9: 1041–1050.PubMedGoogle Scholar
  29. 29.
    Townsend, A. R. M., Rothbard, J., Gotch, E M., Bahadur, G., Wraith, D. and A. J. McMichael (1986) The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides. Cell 44: 959–968.PubMedCrossRefGoogle Scholar
  30. 30.
    Van den Eynde, B., B. Lethe, A. Van Pel, E. De Plaen, T. Boon (1991) The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice. J. Exp. Med. 173: 1373–1384.PubMedCrossRefGoogle Scholar
  31. 31.
    Boon, T., P. Coulie, M. Marchand, P. Weynants, T. Wölfel, V. Brichard (1994) Genes coding for tumor rejection antigens: perspectives for specific immunotherapy. Biologic therapy of cancer updates 4: 1–14.Google Scholar
  32. 32.
    Mandelboim, O., G. Berke, M. Fridkin, M. Feldman, M. Eisenstein, L. Eisenbach (1994) CTL induction by a tumour-associated antigen octapeptide derived from a murine lung carcinoma. Nature 369: 67–71.PubMedCrossRefGoogle Scholar
  33. 33.
    Pardoll, D. M (1994) A new look for the 1990s. Nature 369: 357–358.PubMedCrossRefGoogle Scholar
  34. 34.
    Mandelboim, O., E. Vadai, M. Fridkin, A. Katz-Hillel, M. Feldman, G. Berke, L. Eisenbach (1995) Regression of established murine carcinoma metastases following vaccination with tumour-assiated antigen peptides. Nat. Med. 1: 1179–1183.PubMedCrossRefGoogle Scholar
  35. 35.
    de Bergeyck, V., E. De Plaen, P. Chomez, T. Boon, A. Van Pel (1994) An intracisternal A-particle sequence codes for an antigen recognized by syngeneic cytolytic T lymphocytes on a mouse spontaneous leukemia. Eur. J. Immunol. 24: 2203–2212.PubMedCrossRefGoogle Scholar
  36. 36.
    Uenaka, A., T. Ono, T. Akisawa, H. Wada, T. Yasuda, E. Nakayama (1994) Identification of a unique antigen peptide pRL1 on BALB/c RLo->1 leukemia recognized by cytotoxic T lymphocytes and its relation to the Akt oncogene. J. Exp. Med. 180: 1599–1607.PubMedCrossRefGoogle Scholar
  37. 37.
    Monach, P. A., S. C. Meredith, C. T. Siegel, H. Schreiber (1995) A unique tumor antigen produced by a single amino acid substitution. Immunity 2: 45–59.PubMedCrossRefGoogle Scholar
  38. 38.
    Melief, C. J. M., W. M. Kast (1993) Potential immunogenicity of oncogene and tumor suppressor gene products. Curr. Opin. Immunol. 5: 709–713.PubMedCrossRefGoogle Scholar
  39. 39.
    Skipper, J., H. J. Stauss (1993) Identification of two cytotoxic T lymphocyte-recognized epitopes in the Ras protein. J. Exp. Med. 177: 1493–8.PubMedCrossRefGoogle Scholar
  40. 40.
    Peace, D. J., J. W. Smith, W. Chen, S. -G. You, W. L. Cosand, J. Blake, M. A. Cheever (1994) Lysis of ras oncogene-transformed cells by specific cytolytic T lymphocytes elicited by primary in vitro immunization with mutated ras peptide. J. Exp. Med. 179: 473–479.PubMedCrossRefGoogle Scholar
  41. 41.
    Noguchi, Y., Y.-T. Chen, L. -J. Old (1994) A mouse mutant p53 product recognized by CD4+ and CD8+ T cells. Proc. Natl. Acad. Sci. USA 91: 3171–3175.PubMedCrossRefGoogle Scholar
  42. 42.
    Prehn, R. T (1993) Tumor immunogenicity: how far can it be pushed? Proc. Natl. Acad. Sci. USA 90: 4332–4333.PubMedCrossRefGoogle Scholar
  43. 43.
    Boon, T., J.-P. Szikora, E. De Plaen, T. Wölfel, A. Van Pel (1989) Cloning and characterization of genes coding for tum transplantation antigens. J. Autoimmun. 2 (Supplement): 109–114.PubMedCrossRefGoogle Scholar
  44. 44.
    Hostetler, L. W., H. N. Ananthaswamy, M. L. Kripke (1986) Generation of tumor-specific transplantation antigens by UV radiation can occur independently of neoplastic transformation. J. Immunol. 137: 2721–2725.PubMedGoogle Scholar
  45. 45.
    Basombrio, M. A (1970) Search for common antigenicities among twenty-five sarcomas induced by methylcholanthrene. Cancer Res. 30: 2458–2462.PubMedGoogle Scholar
  46. 46.
    Ramarathinam, L., M. Castle, Y. Wu, Y. Liu (1994) T cell costimulation by B7/BB1 induces CD8 T cell-dependent tumor rejection: an important role of B7/BB1 in the induction, recruitment, and effector function of antitumor T cells. J. Exp. Med. 179: 1205–1214.PubMedCrossRefGoogle Scholar
  47. 47.
    Hu, J., W. Kindsvogel, S. Busby, M. C. Bailey, Y. Y. Shi, P. D. Greenberg (1993) An evaluation of the potential to use tumor-associated antigens as targets for antitumor T cell therapy using transgenic mice expressing a retroviral tumor antigen in normal lymphoid tissues. J. Exp. Med. 177: 1681–90.PubMedCrossRefGoogle Scholar
  48. 48.
    Hara, I., Y. Takechi, A. N. Houghton (1995) Implicating a role for immune recognition of self in tumor rejection: passive immunization against the Brown locus protein. J. Exp. Med. 182: 1609–1614.PubMedCrossRefGoogle Scholar
  49. 49.
    Morgan, D. A., Ruscetti, F. W., Gallo, R. C (1976) Selective in vitro growth of T lymphocytes from normal human bone marrows. Science 193: 1007.PubMedCrossRefGoogle Scholar
  50. 50.
    Gillis, S., Smith, K (1977) Long term culture of tumor specific cytotoxic T cells. Nature 268: 154.PubMedCrossRefGoogle Scholar
  51. 51.
    Knuth, A., T. Wölfel, K. H. Meyer zum Büschenfelde (1992) T cell responses to human malignant tumors. Cancer Surv. 13: 39–52.PubMedGoogle Scholar
  52. 52.
    Crowley, N. J., T. L. Darrow, M. A. Quinn-Allen, H. E Seigler (1991) MHC-restricted recognition of autologous melanoma by tumor-specific cytotoxic T cells. Evidence for restriction by a dominant HLA-A allele. J. Immunol. 146: 1692–1699.PubMedGoogle Scholar
  53. 53.
    Wölfel, T., M. Hauer, E. Klehmann, V. Brichard, B. Ackermann, A. Knuth, T. Boon, K.–H. Meyer zum Büschenfelde (1993) Analysis of antigens recognized on human melanoma cells by A2-restricted cytolytic T lymphocytes (CTL). Int. J. Cancer 55: 237–244.PubMedCrossRefGoogle Scholar
  54. 54.
    Bernhard, H., J. Karbach, T. Wölfel, P. Busch, S. Störkel, M. Stöckle, C. Wölfel, B. Seliger, C. Huber, K. -H. Meyer zum Büschenfelde, A. Knuth (1994) Cellular immune response to human renal-cell carcinomas: definition of a common antigen recognized by HLA-A2restricted cytotoxic T-lymphocyte (CTL) clones. Int. J. Cancer 59: 837–842.PubMedCrossRefGoogle Scholar
  55. 55.
    Anichini, A., C. Maccalli, R. Mortarini, S. Salvi, A. Mazzocchi, P. Squarcina, M. Herlyn, G. Parmiani (1993) Melanoma cells and normal melanocytes share antigens recognized by HLA-A2-restricted cytotoxic T cell clones from melanoma patients. J. Exp. Med. 177: 989–998.PubMedCrossRefGoogle Scholar
  56. 56.
    Anichini, A., R. Mortarini, C. Maccalli, P. Squarcina, K. Fleischhauer, L. Mascheroni, G. Parmiani (1996) Cytotoxic T cells directed to tumor antigens not expressed on normal melanocytes dominate HLA-A2.1-restricted immune repertoire to melanoma. J. Immunol. 156: 208–217.PubMedGoogle Scholar
  57. 57.
    Knuth, A., T. Wölfel, E. Klehmann, T. Boon, K. H. Meyer zum Büschenfelde (1989) Cytolytic T-cell clones against an autologous human melanoma: Specificity study and definition of three antigens by immunoselection. Proc. Natl. Acad. Sci. USA 86: 2804–2808.PubMedCrossRefGoogle Scholar
  58. 58.
    Van den Eynde, B., P. Hainaut, M. Herin, A. Knuth, C. Lemoine, P. Weynants, P. Van der Bruggen, R. Fauchet, T. Boon (1989) Presence on a human melanoma of multiple antigens recognized by autologous CTL. Int. J. Cancer 44: 634–640.PubMedCrossRefGoogle Scholar
  59. 59.
    Ioannides, C. G., R. S. Freedman, C. D. Platsoucas, S. Rashed, Y. P. Kim (1991) Cytotoxic T cell clones isolated from ovarian tumor-infiltrating lymphocytes recognize multiple antigenic epitopes on autologous tumor cells. J. Immunol. 146: 1700–1707.PubMedGoogle Scholar
  60. 60.
    Lehmann, F., M. Marchand, P. Hainaut, P. Pouillart, X. Sastre, H. Ikeda, T. Boon, P. G. Coulie (1995) Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient consistent with immunoselection. Eur. J. Immunol. 25: 340–347.PubMedCrossRefGoogle Scholar
  61. 61.
    Unanue, E. R (1995) The 1995 Albert Lasker Medical Research Award. The concept of antigen processing and presentation. Jama 274: 1071 - -3.PubMedCrossRefGoogle Scholar
  62. 62.
    Seed, B., A. Aruffo (1987) Molecular cloning of the CD2 antigen, the T-cell erythrocyte receptor, by a rapid immunoselection procedure. Proc. Natl. Acad. Sci. USA 84: 3365–3369.PubMedCrossRefGoogle Scholar
  63. 63.
    Karttunen, J., N. Shastri (1991) Measurement of ligand-induced activation in single viable T cells using the lacZ reporter gene. Proc. Natl. Acad. Sci. USA 88: 3972–3976.PubMedCrossRefGoogle Scholar
  64. 64.
    Karttunen, J., S. Sanderson, N. Shastri (1992) Detection of rare antigen-presenting cells by the lacZ T-cell activation assay suggests an expression cloning strategy for T-cell antigens. Proc. Natl. Acad. Sci. USA 89: 6020–6024.PubMedCrossRefGoogle Scholar
  65. 65.
    Brichard, V., A. Van Pel, T. Wölfel, C. Wölfel, E. De Plaen, B. Lethé, P. Coulie, T. Boon (1993) The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lympocytes on HLA-A2 melanomas. J. Exp. Med. 178: 489–495.PubMedCrossRefGoogle Scholar
  66. 66.
    Coulie, P., V. Brichard, A. Van Pel, T. Wölfel, J. Schneider, C. Traversari, S. Mattei, E. De Plaen, C. Lurquin, J. -P. Szikora, J. -C. Renauld, T. Boon (1994) A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 180: 35–42.PubMedCrossRefGoogle Scholar
  67. 67.
    Van den Eynde, B., O. Peeters, O. De Backer, B. Gaugler, S. Lucas, T. Boon (1995) A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J. Exp. Med. 182: 689–698.PubMedCrossRefGoogle Scholar
  68. 68.
    Coulie, P. G., E Lehmann, B. Lethé, J. Herman, C. Lurquin, M. Andrawiss, T. Boon (1995) A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc. Natl. Acad. Sci. USA 92: 7976–7980.PubMedCrossRefGoogle Scholar
  69. 69.
    Wölfel, T., M. Hauer, J. Schneider, M. Serrano, C. Wölfel, E. Klehmann-Hieb, E. De Plaen, T. Hankeln, K. -H. Meyer zum Büschenfelde, D. Beach (1995) A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 269: 1281–1284.PubMedCrossRefGoogle Scholar
  70. 70.
    Kawakami, Y., S. Eliyahu, C. H. Delgado, P. E Robbins, L. Rivoltini, S. L. Topalian, T Miki, S. A. Rosenberg (1994) Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc. Natl. Acad. Sci. USA 91: 3515–3519.PubMedCrossRefGoogle Scholar
  71. 71.
    Robbins, P. E, E. -G. M., Y. Kawakami, S. A. Rosenberg (1994) Recognition of tyrosinase by tumor-infiltrating lymphocytes from a patient responding to immunotherapy. Cancer Res. 54: 3124–6.PubMedGoogle Scholar
  72. 72.
    Kawakami, Y., S. Eliyahu, C. H. Delgado, P. E Robbins, L. Rivoltini, S. L. Topalian, T Miki, S. A. Rosenberg (1994) Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc. Natl. Acad. Sci. USA. 91: 3515–9.PubMedCrossRefGoogle Scholar
  73. 73.
    Wang, R. E, P. E Robbins, Y. Kawakami, X. Q. Kang, S. A. Rosenberg (1995) Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes. J. Exp. Med. 181: 799–804.PubMedCrossRefGoogle Scholar
  74. 74.
    Robbins, P. E, M. El Gamil, Y. E Li, S. L. Topalian, L. Rivoltini, K. Sakaguchi, E. Appella, Y. Kawakami, S. A. Rosenberg (1995) Cloning of a new gene encoding an antigen recognized by melanoma-specific HLA-A24-restricted tumor-infiltrating lymphocytes. J. Immunol. 154: 5944–50.PubMedGoogle Scholar
  75. 75.
    Bjorkman, P. J., M. A. Saper, B. Samraoui, W. S. Bennett, J. L. Strominger, D. C. Wiley (1987) The foreign antigen binding site and T cell recognition regions of class I histocompatibility antigens. Nature 329: 512–518.PubMedCrossRefGoogle Scholar
  76. 76.
    Rammensee, H. -G., T. Friede, S. Stevanovic (1995) MHC ligands and peptide motifs: first listing. Immunogenetics 41: 178–228.PubMedCrossRefGoogle Scholar
  77. 77.
    Cox, A. L., J. Skipper, Y. Chen, R. A. Henderson, T. L. Darrow, J. Shabanowitz, V. H. Engelhard, D. E Hunt, C. L. Slingluff Jr (1994) Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 264: 716–719.PubMedCrossRefGoogle Scholar
  78. 78.
    van der Bruggen, P., C. Traversari, P. Chomez, C. Lurquin, E. De Plaen, B. Van den Eynde, A. Knuth, T. Boon (1991) A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254: 1643–1647.PubMedCrossRefGoogle Scholar
  79. 79.
    van der Bruggen, P., J. -P. Szikora, P. Boel, C. Wildmann, M. Somville, M. Sensi, T. Boon (1994) Autologous cytolytic T lymphocytes recognize a MAGE-1 nonapeptide on melanomas expressing HLA-Cw^’1601. Eur. J. Immunol. 24: 2134–2140.PubMedCrossRefGoogle Scholar
  80. 80.
    van der Bruggen, P., J. Bastin, T. Gajewski, P. G. Coulie, P. Boel, D. S. C., C. Traversari, A. Townsend, T. Boon (1994) A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur. J. Immunol. 24: 3038–43.Google Scholar
  81. 81.
    Gaugler, B., B. Van den Eynde, P. van der Bruggen, P. Romero, J. J. Gaforio, E. De Plaen, B. Lethé, F. Brasseur, T. Boon (1994) Human gene MAGE-3 codes for a antigen recog- nized on a melanoma by autologous cytolytic T lymphocytes. J. Exp. Med. 179: 921–930.PubMedCrossRefGoogle Scholar
  82. 82.
    Boel, P., C. Wildmann, M. L. Sensi, R. Brasseur, J. -C. Renauld, P. Coulie, T. Boon, P. van der Bruggen (1995) BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity 2: 167–175.PubMedCrossRefGoogle Scholar
  83. 83.
    Van Pel, A., P. van der Bruggen, P. G. Coulie, V. G. Brichard, B. Lethé, B. Van den Eynde, C. Uyttenhove, J. -C. Renauld, T. Boon (1995) Genes coding for tumor antigens recognized by cytolytic T lymphocytes. Immunol. Rev. 145: 229–249.PubMedCrossRefGoogle Scholar
  84. 84.
    Brasseur, E, a. others (1995) Expression of MAGE genes in primary and metastatic cutaneous melanoma. Int. J. Cancer 63: 375–380.PubMedCrossRefGoogle Scholar
  85. 85.
    Anichini, A., Fossati, G. and Parmiani, G (1987) Clonal analysis of the cytolytic T cell response to human tumors. Immunol. Today 8: 385–389.CrossRefGoogle Scholar
  86. 86.
    Crowley, N. J., C. L. Slingluff, T. L. Darrow, H. F. Seigler (1990) Generation of human autologous melanoma-specific cytotoxic T-cells using HLA-A2 matched allogeneic melanomas. Cancer Res. 50: 492–498.PubMedGoogle Scholar
  87. 87.
    Viret, C., E Davodeau, Y. Guilloux, J. -D. Bignon, G. Semana, R. Breathnach, E Jotereau (1993) Recognition of shared melanoma antigen by HLA-A2-restricted cytolytic T cell clones derived from human tumor-infiltrating lymphocytes. Eur. J. Immunol. 23: 141–146.PubMedCrossRefGoogle Scholar
  88. 88.
    Wölfel, T., A. Van Pel, V. Brichard, J. Schneider, B. Seliger, K. -H. Meyer zum Büschenfelde, T. Boon (1994) Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur. J. Immunol. 24: 759–764.PubMedCrossRefGoogle Scholar
  89. 89.
    Chen, Q., P. Hersey (1992) MHC-restricted responses of CD8+ and CD4+ T-cell clones from regional lymph nodes of melanoma patients. Int. J. Cancer 51: 218–24.PubMedCrossRefGoogle Scholar
  90. 90.
    Stam, N. J., T. N. Vroom, P. J. Peters, E. B. Pastoors, H. L. Ploegh. submitted.HC-A2.Google Scholar
  91. 91.
    Spies, T., V. Cerundolo, M. Colonna, P. Cresswell, A. Townsend, R. De Mars (1992) Presentation of viral antigen by MHC class I molecules is dependent on a putative peptide transporter heterodimer. Nature 355: 644–646.PubMedCrossRefGoogle Scholar
  92. 92.
    Restifo, N. P., F. Esquivel, Y. Kawakami, J. W. Yewdell, J. J. Mule, S. A. Rosenberg, J. R. Bennink (1993) Identification of human cancers deficient in antigen-processing. J. Exp. Med. 177: 265–272.PubMedCrossRefGoogle Scholar
  93. 93.
    Wei, M. L., P. Cresswell (1992) HLA-A2 molecules in an antigen-processing mutant cell contain signal sequence-derived peptides. Nature 356: 443–446.PubMedCrossRefGoogle Scholar
  94. 94.
    Skipper, J. C. A., R. C. Hendrickson, P. H. Gulden, V. Brichard, A. Van Pel, Y. Chen, J. Shabanowitz, T. Wölfel, J. Slingluff, G. L., T. Boon, D. E Hunt, V. H. Engelhard (1996) An HLA-A2-restricted tyrosinase antigen on melanoma cells resulted from posttranslational modification and suggests a novel pathway for processing of membrane proteins. J. Exp. Med. 183: 527–534.Google Scholar
  95. 95.
    Kang, X., Y. Kawakami, G. M. el, R. Wang, K. Sakaguchi, J. R. Yannelli, E. Appella, S. A. Rosenberg, P. E Robbins (1995) Identification of a tyrosinase epitope recognized by HLA-A24-restricted, tumor-infiltrating lymphocytes. J. Immunol. 155: 1343–8.PubMedGoogle Scholar
  96. 96.
    Brichard, V. G., J. Herman, A. Van Pel, C. Wildman, B. Gaugler, T. Wölfel, T. Boon, B. Lethé (1996) A tyrosinase nonapeptide presented by HLA-B44 is recognized on a human melanoma by autologous cytolytic T lymphocytes. Eur. J. Immunol. 26: 224–230.PubMedCrossRefGoogle Scholar
  97. 97.
    Topalian, S. L (1994) MHC class II restricted tumor antigens and the role of CD4+ T cells in cancer immunotherapy. Curr. Opin. Immunol. 6: 741–745.PubMedCrossRefGoogle Scholar
  98. 98.
    Visseren, M. J., E. A. van, d. V. E. van, M. E. Ressing, W. M. Kast, P. I. Schrier, C. J. Melief (1995) CTL specific for the tyrosinase autoantigen can be induced from healthy donor blood to lyse melanoma cells. J. Immunol. 154: 3991–8.PubMedGoogle Scholar
  99. 99.
    Herr, W., J. Schneider, A. W. Lohse, K. -H. Meyer zum Büschenfelde, T. Wölfel (1996) Detection and quantification of blood-derived CD8+ T lymphocytes secreting tumor necrosis factor alpha in response to HLA-A2.1-binding melanoma and viral peptide antigens. J. Immunol. Meth. 191: 131–142.CrossRefGoogle Scholar
  100. 100.
    Kwon, B. S., C. Chintamaneni, C. A. Kozak, N. G. Copeland, D. J. Gilbert, N. Jenkins, D. Barton, U. Francke, Y. Kobayashi, K. K. Kim (1991) A melanocyte-specific gene, Pmel 17, maps near the silver coat color locus on mouse chromosome 10 and is in a syntenic region on human chromosome 12. Proc. Natl. Acad. Sci. USA. 88: 9228–32.PubMedCrossRefGoogle Scholar
  101. 101.
    Bakker, A. B. H., M. W. J. Schreurs, A. J. de Boer, Y. Kawakami, S. A. Rosenberg, G. J. Adema, C. G. Figdor (1994) Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J. Exp. Med. 179: 1005–1009.PubMedCrossRefGoogle Scholar
  102. 102.
    Kawakami, Y., S. Eliyahu, C. Jennings, K. Sakaguchi, X. Kang, S. Southwood, P. E Robbins, A. Sette, E. Appella, S. A. Rosenberg (1995) Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J. Immunol. 154: 3961–3968.PubMedGoogle Scholar
  103. 103.
    Kawakami, Y., S. Eliyahu, K. Sakaguchi, P. E Robbins, L. Rivoltini, J. R. Yannelli, E. Appella, S. A. Rosenberg (1994) Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J. Exp. Med. 180: 347–52.PubMedCrossRefGoogle Scholar
  104. 104.
    Slingluff, C. L., A. L. Cox, R. A. Henderson, D. E Hunt, V. H. Engelhard (1993) Recognition of human melanoma cells by HLA-A2.1-restricted cytotoxic T lymphocytes is mediated by at least six shared peptide epitopes. J. Immunol. 150: 2955–2963.PubMedGoogle Scholar
  105. 105.
    Wölfel, T., J. Schneider, K. -H. Meyer zum Büschenfelde, H. -G. Rammensee, O. Rötzschke, K. Falk (1994) Isolation of naturally processed peptides recognized by cytolytic T lymphocytes (CTL) on human melanoma cells in association with HLA-A2.1. Int. J. Cancer 57: 413–418.PubMedCrossRefGoogle Scholar
  106. 106.
    Castelli, C., W. J. Storkus, M. J. Maeurer, D. M. Martin, E. C. Huang, B. N. Pramanik, T. L. Nagabhushan, G. Parmiani, M. T. Lotze (1995) Mass spectrometric identification of a naturally processed melanoma peptide recognized by CD8+ cytotoxic T lympho-cytes. J. Exp. Med. 181: 363–8.PubMedCrossRefGoogle Scholar
  107. 107.
    Mattes, M. J., T. M. Thomson, L. J. Old, K. O. Lloyd (1983) A pigmentation associated, differentiation antigen of human melanoma defined by a precipitating antibody in human serum. Int. J. Cancer 32: 717.PubMedCrossRefGoogle Scholar
  108. 108.
    Jimenez-Cervantes, C., F. Solano, T. Kobayashi, K. Urabe, V. J. Hearing, J. A. Lozano, J. C. Garcia-Borron (1994) A new enzymatic function in the melanogenic pathway. J. Biol. Chem. 269: 17993–18001.PubMedGoogle Scholar
  109. 109.
    Thomsen, T. M., E X. Real, S. Murakami, C. Cordon-Cardi, L. J. Old, A. N. Houghton (1988) differentiation antigens of melanocytes and melanoma: analysis of melanosome and cell surface markers of human pigmented cells with monoclonal antibodies. J. Invest. Dermatol. 90: 459–466.Google Scholar
  110. 110.
    Bakker, A. B., G. Marland, A. J. de Boer, R. J. Hujbens, E. H. Danen, G. J. Adema, C. G. Figdor (1995) Generation of anti-melanoma cytotoxic T lymphocytes from healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells in vitro. Cancer Res. 15: 5330–5334.Google Scholar
  111. 111.
    Finn, O. J., K. R. Jerome, R. A. Henderson, G. Pecher, N. Domenech, J. MagarianBlander, S. M. Barratt-Boves (1995) MUC-1 epithelial tumor mucin-based immunity and cancer vaccines. Immunol. Rev. 145: 61–89.PubMedCrossRefGoogle Scholar
  112. 112.
    Rajan, T. V (1987) Is there a role for MHC class I antigens in the elimination of somatic mutants? Immunol. Today 8: 171–172.CrossRefGoogle Scholar
  113. 113.
    Kamb, A., N. A. Gruis, J. Weaver-Feldhaus, Q. Liu, K. Harshman, S. V. Tavtigian, E. Stockert, R. S. Day III, B. E. Johnson, M. H. Skolnick (1994) A cell cycle regulator potentially involved in genesis of many tumor types. Science 264: 436–440.PubMedCrossRefGoogle Scholar
  114. 114.
    Mori, T., K. Miura, T. Aoki, S. Mori, Y. Nakamura (1994) Frequent somatic mutation of the MTS1/CDK4I (multiple tumor suppressor/cyclin-dependent kinase 4 inhibitor) gene in esophageal squamous cell carcinoma. Cancer Res. 54: 3396–3397.PubMedGoogle Scholar
  115. 115.
    Kast, W. M., R. Offringa, P. J. Peters, A. C. Voordouw, R. H. Meloen, A. J. van der Eb, C. J. M. Melief (1989) Eradication of adenovirus E1-induced tumors by E1A-specific cytotoxic lymphocytes. Cell 59: 603–614.PubMedCrossRefGoogle Scholar
  116. 116.
    Zuo, L., J. Weger, B. Yang, A. M. Goldstein, M. A. Tucker, N. Hayward, N. C. Dracopoli (1996) Germline mutations in the p16INK4A binding domain of CDK4 in familial melanoma. Nat. Genet. 12: 97–99.PubMedCrossRefGoogle Scholar
  117. 117.
    Cheever, M. A., M. L. Disis, H. Bernhard, J. R. Gralow, S. L. Hand, E. S. Huseby, H. L. Qin, M. Takahashi, W. Chen (1995) Immunity to oncogenic proteins. Immunol. Rev. 145: 33–59.PubMedCrossRefGoogle Scholar
  118. 118.
    Nijman, H. W., d. B. S. Van, M. P. Vierboom, J. G. Houbiers, W. M. Kast, C. J. Melief (1994) p53, a potential target for tumor-directed T cells. Immunol. Lett. 40: 171–8.Google Scholar
  119. 119.
    Ioannides, C. G., B. Fisk, D. Fan, W. E. Biddison, J. T. Wharton, C. A. O’Brian (1993) Cytotoxic T cells isolated from ovarian malignant ascites recognize a peptide derived from the HER-2/neu proto-oncogene. Cell. Immunol. 151: 225–234.PubMedCrossRefGoogle Scholar
  120. 120.
    Peoples, G. E., I. Yoshino, C. C. Douville, J. V. Andrews, P. S. Goedegebuure, T. J. Eberlein (1994) TCR V beta 3+ and V beta 6+ CTL recognize tumor-associated antigens related to HER2/neu expression in HLA-A2+ ovarian cancers. J. Immunol. 152: 4993–9.PubMedGoogle Scholar
  121. 121.
    Fisk, B., B. Chesak, M. S. Pollack, J. T. Wharton, C. G. Ioannides (1994) Oligopeptide induction of a cytotoxic T lymphocyte response to HER-2/neu proto-oncogene in vitro. Cell. Immunol. 157: 415–27.CrossRefGoogle Scholar
  122. 122.
    Chen, W., D. J. Peace, D. K. Rovira, S. -G. You, M. A. Cheever (1992) T-cell immunity to the joining region of p210BCR-ABL protein. Proc. Natl. Acad. Sci. USA 89: 1486–1472.Google Scholar
  123. 123.
    Houbiers, J. G. A., H. W. Nijman, S. H. Van der Burg, J. W. Drijfhout, P. Kenemans, C. J. H. Van de Velde, A. Brand, E Momburg, W. M. Kast, C. J. M. Melief (1993) In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild type p53. Eur. J. Immunol. 23: 2072–2077.Google Scholar
  124. 124.
    Fossum, B., T. I. Gedde-Dahl, J. Breivik, J. A. Eriksen, A. Spurkland, E. Thorsby, G. Gaudernack (1994) p21-ras-peptide-specific T-cell responses in a patient with colorectal cancer. CD4+ and CD8+ T cells recognize a peptide corresponding to a common mutation (13Gly-Asp). Int. J. Cancer 56: 40–45.Google Scholar
  125. 125.
    Spagnoli, G. C., C. Schaefer, T. E. Willimann, T. Kocher, A. Amoroso, A. Juretic, M. Zuber, U. Luscher, E Harder, M. Heberer (1995) Peptide-specific CTL in tumor infiltrating lymphocytes from metastatic melanomas expressing MART-1/Melan-A, gp100 and Tyrosinase genes: a study in an unselected group of HLA-A2.1-positive patients. Int. J. Cancer 64: 309–15.PubMedCrossRefGoogle Scholar
  126. 126.
    Townsend, S. E., J. P. Allison (1993) Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science 259: 368–370.PubMedCrossRefGoogle Scholar
  127. 127.
    Becker, J. C., T. Brabletz, C. Czerny, C. Termeer, E. B. Brocker (1993) Tumor escape mechanisms from immunosurveillance: induction of unresponsiveness in a specific MHC-restricted CD4+ human T cell clone by the autologous MHC class II+ melanoma. Int. Immunol. 5: 1501–8.PubMedCrossRefGoogle Scholar
  128. 128.
    Lanzavecchia, A (1993) Identifying strategies for immune intervention. Science 260: 937–944.PubMedCrossRefGoogle Scholar
  129. 129.
    Luscher, U., L. Filgueira, A. Juretic, M. Zuber, N. J. Luscher, M. Heberer, G. C. Spagnoli (1994) The pattern of cytokine gene expression in freshly excised human metastatic melanoma suggests a state of reversible anergy of tumor-infiltrating lymphocytes. Int. J. Cancer 57: 612–9.PubMedCrossRefGoogle Scholar
  130. 130.
    Becker, J. C., C. Czerny, E. B. Brocker (1994) Maintenance of clonal anergy by endogenously produced IL-10. Int. Immunol. 6: 1605–12.PubMedCrossRefGoogle Scholar
  131. 131.
    von Boehmer, H (1992) Thymic selection: a matter of life and death. Immunol. Today 13: 454–8.PubMedCrossRefGoogle Scholar
  132. 132.
    Arnold, B., G. Schönrich, G. J. Hämmerling (1993) Multiple levels of peripheral tolerance. Immunol. Today 14: 12–14.PubMedCrossRefGoogle Scholar
  133. 133.
    Naughton, G. K., M. Eisinger, J. C. Bystryn (1983) Antibodies to normal human melanocytes in vitiligo. J. Exp. Med. 158: 246–251.PubMedCrossRefGoogle Scholar
  134. 134.
    Song, Y. H., E. Connor, Y. Li, B. Zorovich, P. Balducci, N. Maclaren (1994) The role of tyrosinase in autoimmune vitiligo. Lancet 344: 1049–52.PubMedCrossRefGoogle Scholar
  135. 135.
    Nordlund, J. J., J. M. Kirkwood, B. M. Forget, G. Milton, D. M. Albert, A. B. Lerner (1983) Vitiligo in patients with metastatic melanoma: a good prognostic sign. J. Amer. Acad. Derm. 9: 689–696.CrossRefGoogle Scholar
  136. 136.
    Bystryn, J. -C., R. Darrell, R. J. Friedman, A. Kopf (1987) Prognostic significance of hypopigmentation in malignant melanoma. Arch. Dermatol. 123: 1053–1055.PubMedCrossRefGoogle Scholar
  137. 137.
    Duhra, P., A. Ilchyshin (1991) Prolonged survival in metastatic malignant melanoma associated with vitiligo. Clin. Exp. Dermatol. 16: 303–305.PubMedCrossRefGoogle Scholar
  138. 138.
    Richards, J. M., N. Mehta, K. Ramming, P. Skosey (1992) Sequential chemoimmunotherapy in the treatment of metastatic melanoma. J. Clin. Oncol. 10: 1338–1343.PubMedGoogle Scholar
  139. 139.
    Livingston, P. 0., G. Y. C. Wong, S. Adluri, Y. Tao, M. Padavan, R. Parente, C. Hanlon, M. Jones Calves, F. Helling, G. Ritter, H. F. Oettgen, L. J. Old (1994) Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J. Clin. Oncol. 12: 1036–1044.Google Scholar
  140. 140.
    Mackensen, A., G. Carcelain, S. Viel, M. -C. Raynal, H. Michalaki, E Triebel, J. Bosq, T. Hercend (1994) Direct evidence to support the immunosurveillance concept in a human regressive melanoma. J. Clin. Invest. 93: 1397–1402.PubMedCrossRefGoogle Scholar
  141. 141.
    Ellis, J. R. M., P. J. Keating, J. Baird, E. F. Hounsell, D. V. Renouf, M. Rowe, D. Hopkins, M. S. Duggan-Keen, J. S. Bartholomew, L. S. Young, P. L. Stern (1995) The association of an HPV 16 oncogene variant with HLA-B7 has implications for vaccine design in cervical cancer. Nat. Med. 1: 464–470.PubMedCrossRefGoogle Scholar
  142. 142.
    Christinck, L. R., M. A. Luscher, B. H. Barber, D. B. Williams (1991) Peptide binding to class I MHC on living cells and quantitation of complexes required for CTL lysis. Nat. 352: 67–70.CrossRefGoogle Scholar
  143. 143.
    Neefjes, J. J., F. Momburg (1993) Cell biology of antigen presentation. Curr. Opin. Immunol. 5: 27–34.PubMedCrossRefGoogle Scholar
  144. 144.
    Garrido, E, T. Cabrera, A. Concha, S. Glew, F. Ruiz-Cabello, P. L. Stern (1993) Natural history of HLA during tumor development. Immunol. Today 14.Google Scholar
  145. 145.
    Ferrone, S., F. M. Marincola (1995) Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol. Today 16: 487–494.PubMedCrossRefGoogle Scholar
  146. 146.
    Hruban, R. H., d. R. P. van, Y. S. Erozan, D. Sidransky (1994) Brief report: molecular biology and the early detection of carcinoma of the bladder — the case of Hubert H. Humphrey. N. Engl. J. Med. 330: 1276–8.PubMedCrossRefGoogle Scholar
  147. 147.
    Cohen, J (1994) Vaccines get a new twist. Science (Research News) 264: 503–505.Google Scholar
  148. 148.
    Golumbek, P. T., A. J. Lazenby, H. I. Levitsky, L. M. Jaffee, H. Karasuyama, M. Baker, D. M. Pardoll (1991) Treatment of established renal cancer by tumor cells engineered to secret interleukin-4. Science 245: 713–716.CrossRefGoogle Scholar
  149. 149.
    Majordomo, J. I., T. Zorina, W. J. Storkus, L. Zitvogel, C. Celluzzi, L. D. Falo, C. J. Melief, S. T. Ildstad, W. M. Kast, A. B. Deleo, M. T. Lotze (1995) Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat. Med. 1: 1297–1302.CrossRefGoogle Scholar
  150. 150.
    Zitvogel, L., J. I. Mayordomo, T. Tjandrawan, A. B. DeLeo, M. R. Clarke, M. T. Lotze, W. J. Storkus (1996) Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell-associated cytokines. J. Exp. Med. 183: 87–97.PubMedCrossRefGoogle Scholar
  151. 151.
    Kwak, L. W., M. J. Campbell, D. K. Czerwinski, S. Hart, R. A. Miller, R. Levy (1992) Induction of immune responses in patients with B-cell lymphoma against the surface-immunglobulin idiotype expressed by their tumors. N. Engl. J. Med. 327: 1209–1215.PubMedCrossRefGoogle Scholar
  152. 152.
    Mukherji, B., N. G. Chakraborty, S. Yamasaki, T. Okino, H. Yamase, J. R. Sporn, S. K. Kurtzman, M. T. Ergin, J. Ozols, J. Meehan, F. Mauri (1995) Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. Proc. Natl. Acad. Sci. USA 92: 8078–8082.PubMedCrossRefGoogle Scholar
  153. 153.
    Marchand, M., P. Weynants, E. Rankin, E Arienti, E Belli, G. Parmiani, N. Cascinelli, A. Bourlond, R. Vanwijck, Y. Humblet, J. -L. Canon, C. Laurent, J. -M. Naeyaert, R. Plagne, R. Deraemaeker, A. Knuth, E. Jäger, F. Brasseur, J. Herman, P. G. Coulie, T. Boon (1995) Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int. J. Cancer 63: 883–885.PubMedCrossRefGoogle Scholar
  154. 154.
    Finke, J. H., A. H. Zea, J. Stanley, D. L. Longo, H. Mizoguchi, R. R. Tubbs, R. H. Wiltrout, J. J. O’Shea, S. Kudoh, E. Klein, a. 1. et (1993) Loss of T-cell receptor zeta chain and p561ck in T-cells infiltrating human renal cell carcinoma. Cancer Res. 53: 5613–6.Google Scholar
  155. 155.
    Nakagomi, H., M. Petersson, I. Magnusson, C. Juhlin, M. Matsuda, H. Mellstedt, J. L. Taupin, E. Vivier, P. Anderson, R. Kiessling (1993) Decreased expression of the signaltransducing zeta chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma. Cancer Res. 53: 5610–2.PubMedGoogle Scholar
  156. 156.
    Gjertsen, M. K., A. Bakka, J. Breivik, I. Saeterdal, B. G. Solheim, O. Soreide, E. Thorsby, G. Gaudernack (1995) Vaccination with mutant ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding RAS mutaton. Lancet 346: 1399–1340.PubMedCrossRefGoogle Scholar
  157. 157.
    Alving, C. R., V. Koulchin, G. M. Glenn, M. Rao (1995) Liposomes as carriers of peptide antigens: induction of antibodies and cytotoxic T lymphocytes to conjugated and unconjugated peptides. Immunol. Rev. 145: 5–31.PubMedCrossRefGoogle Scholar
  158. 158.
    Falo Jr., L. D., M. Kovacsovics-Bankowski, K. Thompson, K. L. Rock (1995) Targeting antigen into the phagocytic pathway in vivo induces protective tumour immunity. Nat. Med. 1: 649–653.PubMedCrossRefGoogle Scholar
  159. 159.
    Hanson, M. S., C. V. Lapcevich, S. L. Haun (1995) Progress on development of the live BCG recombinant vaccine vehicle for combined vaccine delivery. Ann. N.Y. Acad. Sci. 754: 214–21.PubMedCrossRefGoogle Scholar
  160. 160.
    Sercarz, E. E., P. V. Lehmann, A. Ametani, G. Benichou, A. Miller, K. Moudgil (1993) Dominance and crypticity of T cell antigenic determinants. Annu. Rev. Immunol. 11: 729-.Google Scholar
  161. 161.
    Jansson, L., P. Diener, A. Engström, T. Olsson, R. Holmdahl (1995) Spreading of the immune response to different myelin basic protein peptides in chronic experimental autoimmune encephalomyelitis in B10.RIII mice. Eur. J. Immunol. 25: 2195–2200.PubMedCrossRefGoogle Scholar
  162. 162.
    Aichele, P., K. Brduscha-Riem, R. M. Zinkernagel, H. Hengartner, H. Pircher (1995) T cell priming versus T ell tolerance induced by synthetic peptides. J. Exp. Med. 182: 261–266.PubMedCrossRefGoogle Scholar
  163. 163.
    Moskophidis, D., E Lechner, H. Pircher, R. M. Zinkernagel (1993) Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells. Nature 362: 758-.Google Scholar
  164. 164.
    Kearney, E. R., K. A. Pape, D. Y. Loh, M. K. Jenkins (1994) Visualization of peptide-specific T cell immunity and peripheral tolerance induction in vivo. Immunity 1: 327.Google Scholar
  165. 165.
    Suhrbier, A., S. R. Burrows, A. Fernan, M. E Lavin, G. D. Baxter, D. J. Moss (1993) Peptide epitope induced apoptosis of human cytotoxic T lymphocytes. J. Immunol. 150: 2169.PubMedGoogle Scholar
  166. 166.
    Widman, C., P. Romero, J. L. Maryanski, G. Corradin, D. Valmori (1992) T helper epitopes enhance the cytotoxic response of mice immunized with MHC class I-restricted malaria peptides. J. Immunol. Method. 155: 95–99.CrossRefGoogle Scholar
  167. 167.
    Rock, K. L (1996) A new foreign policy: MHC class I molecules monitor the outside world. Immunol. Today 17: 131–137.PubMedCrossRefGoogle Scholar
  168. 168.
    Schlag, P., M. Manasterski, T. Gerneth, P. Hohenberger, M. Dueck, C. Herfarth, W. Liebrich, V. Schirrmacher (1992) Active specific immunotherapy with Newcastle-dis-ease-virus-modified autologous tumor cells following resection of liver metastases in colorectal cancer. Cancer Immunol. Immunother. 35: 325–330.PubMedCrossRefGoogle Scholar
  169. 169.
    Srivastava, P. K., H. Udono, N. E. Blachere, Z. Li (1994) Heat shock proteins transfer peptides during antigen processing and CTL priming. Immunogenetics 39: 93–8.PubMedCrossRefGoogle Scholar
  170. 170.
    Papadopoulos, E. B., M. Ladanyi, D. Emanuel, S. Mackinnon, E Boulad, M. H. Carabasi, H. Castro-Malaspina, B. H. Childs, A. P. Gillio, T. N. Small, J. W. Young, N. A. Kernan, R. J. O’Reilly (1994) Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N. Engl. J. Med. 330: 1185–1191.PubMedCrossRefGoogle Scholar
  171. 171.
    Porter, D. L., M. S. Roth, C. McGarigle, J. L. M. Ferrara, J. H. Antin (1994) Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N. Engl. J. Med. 330: 100–106.PubMedCrossRefGoogle Scholar
  172. 172.
    Kwak, L. W., D. D. Taub, P. L. Duffey, W. I. Bensinger, E. M. Bryant, C. W. Reynolds, D. L. Longo (1995) Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor. Lancet 345: 1016–1020.PubMedCrossRefGoogle Scholar
  173. 173.
    Kawakami, Y., S. Eliyahu, C. H. Delgado, P. E Robbins, K. Sakaguchi, E. Appella, J. R. Yannelli, G. J. Adema, T. Miki, S. A. Rosenberg (1994) Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc. Natl. Acad. Sci. USA. 91: 6458–62.PubMedCrossRefGoogle Scholar
  174. 174.
    Celis, E., V. Tsai, C. Crimi, R. DeMars, P. A. Wentworth, R. W. Chesnut, H. M. Grey, A. Sette, H. M. Serra (1994) Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptides. Proc. Natl. Acad. Sci. USA 91: 2105–2109.PubMedCrossRefGoogle Scholar
  175. 175.
    Topalian, S. L., L. Rivoltini, M. Mancini, N. R. Markus, P. E Robbins, Y. Kawakami, S. A. Rosenberg (1994) Human CD4+ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene. Proc. Natl. Acad. Sci. USA. 91: 9461–5.PubMedCrossRefGoogle Scholar
  176. 176.
    Peoples, G. E., P. S. Goedegebuure, J. V. Andrews, D. D. Schoof, T. J. Eberlein (1993) HLA-A2 presents shared tumor-associated antigens derived from endogenous proteins in ovarian cancer. J. Immunol. 151: 5481–91.PubMedGoogle Scholar

Copyright information

© Birkhäuser Verlag Basel 1999

Authors and Affiliations

  • Th. Wölfel

There are no affiliations available

Personalised recommendations